atropine sulfate sterop 0.5 mg/1 ml inj. sol. s.c./i.v. amp.
laboratoires sterop sa-nv - atropine sulfate 0,5 mg/ml - solution for injection - 0,50 mg/1 ml - atropine sulfate 0.5 mg/ml - atropine
atropine sulfate sterop 0.25 mg/1 ml inj. sol. s.c./i.v. amp.
laboratoires sterop sa-nv - atropine sulfate 0,25 mg/ml - solution for injection - 0,25 mg/1 ml - atropine sulfate 0.25 mg/ml - atropine
atropine sulfate noridem 1 mg/ml inj. sol. s.c./i.v./i.m. vial
noridem enterprises ltd. - atropine sulfate 1 mg/ml - solution for injection - 1 mg/ml - atropine sulfate 1 mg/ml - atropine
atropine sulfate injection, solution
accord healthcare inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. risk summary there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations) . available data from published observational studies on atropine use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . animal reproduction studies have not been conducted with atropine. clinical considerations disease-associated maternal and/or embryo/fetal risk severe or life-threatening muscarinic events such as acute organophosphate poisoning and symptomatic bradycardia are medical emergencies in pregnancy which can be fatal if left unt
atropine sulfate accord 0.1 mg/ml inj. sol. i.v./i.m. pre-filled syr.
accord healthcare b.v. - atropine sulfate monohydrate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate monohydrate 0.1 mg/ml - atropine
atropine sulfate accord 0.1 mg/ml inj. sol. i.v./i.m. pre-filled syr.
accord healthcare b.v. - atropine sulfate monohydrate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate monohydrate 0.1 mg/ml - atropine
atropine sulfate injection
international medication systems, limited - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. animal reproduction studies have not been conducted with atropine. it also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. trace amounts of atropine was found in breast milk. the clinical impact of this is not known. recommendations for use in pediatric patients are not based on clinical trials. an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disea
atropine sulfate injection, solution
accord healthcare inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. none. risk summary limited available data with atropine sulfate injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes (see data). there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations). animal reproduction studies have not been conducted with atropine sulfate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinicall
atropine sulfate injection, solution
medical purchasing solutions, llc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. risk summary there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations) . available data from published observational studies on atropine use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . animal reproduction studies have not been conducted with atropine. clinical considerations disease-associated maternal and/or embryo/fetal risk severe or life-threatening muscarinic events such as acute organophosphate poisoning and symptomatic bradycardia are medical emergencies in pregnancy
atropine sulfate injection, solution
medical purchasing solutions, llc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. none. risk summary there are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see clinical considerations) . available data from published observational studies on atropine use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . animal reproduction studies have not been conducted with atropine. clinical considerations disease-associated maternal and/or embryo/fetal risk severe or life-threatening muscarinic events such as acute organophosphate poisoning and symptomatic bradycardia are medical emergencies in pregnancy